Xvivo Perfusion AB (LTS:0RKL)
kr 483.29903 12.16762 (2.58%) Market Cap: 15.40 Bil Enterprise Value: 14.98 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q1 2024 Xvivo Perfusion AB Earnings Call Transcript

Apr 24, 2024 / 12:00PM GMT
Release Date Price: kr373.83 (+18.26%)
Christoffer Rosenblad
Xvivo Perfusion AB - Chief Executive Officer

Thank you so much and welcome toXvivo earning call for the first quarter of 2024. Today, we will start the presentation with the front picture. The slide in front of you right now is a picture of Alex from Australia. If you see the heart transplant statistics with Xvivo's heart technology, I think is a important reminder to why we actually are here and it's to make sure that no one dies waiting for new organ.

And with that, we go to the next slide, which is just today's presenters, and that's me Christoffer Rosenblad, CEO and to the left of me today in the same room once I have my CFO, Kristoffer Nordström.

Kristoffer Nordstrom
Xvivo Perfusion AB - Chief Financial Officer

Hi, everyone.

Christoffer Rosenblad
Xvivo Perfusion AB - Chief Executive Officer

And with that we go over to slide 3, which is just a quick glance on Q1. I'm both proud and happy to report the strongest quarter in Xvivo's history and that Q1 shows improvement in all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot